A Multicentre, Multinational, Open-Label, 52-Week Extension Study of Gemigliptin (LC15-0444) Monotherapy in Patients with Type 2 Diabetes Mellitus

The purpose of this extension study was to assess the long-term efficacy and safety of gemigliptin 50 mg in patients with type 2 diabetes mellitus (T2DM). Patients with T2DM who had completed the initial 24-week study comparing gemigliptin monotherapy with placebo were eligible to enrol. In the open...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Sae Jeong, Min, Kyung Wan, Gupta, Sandeep Kumar, Park, Joong Yeol, Shivane, Vyankatesh K., Agarwal, Pankaj Kumar, Kim, Doo Man, Kim, Yong Seung, Baik, Sei Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Diabetes Association 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369212/
https://www.ncbi.nlm.nih.gov/pubmed/33081425
http://dx.doi.org/10.4093/dmj.2020.0047

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369212/
https://www.ncbi.nlm.nih.gov/pubmed/33081425
http://dx.doi.org/10.4093/dmj.2020.0047

Ejemplares similares